<DOC>
	<DOC>NCT01199289</DOC>
	<brief_summary>The purpose of this study is to determine if AMG 827 is effective compared to placebo as measured by change in Asthma Control Questionnaire (ACQ) composite scores.</brief_summary>
	<brief_title>A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Men or women 18 to 65 years of age Percent of predicted FEV1 ≥ 50% and ≤ 80% At least 12% reversibility over prebronchodilator FEV1 Inhaled corticosteroid (ICS) ≥ 200 and ≤ 1000 µg/day fluticasone or equivalent. Ongoing asthma symptoms with ACQ composite score ≥ 1.5 points Respiratory infection within 4 weeks of screening visit or 1 week of baseline visit History of chronic obstructive pulmonary disease or other chronic pulmonary condition other than asthma Any uncontrolled or clinically significant systemic disease (eg, uncontrolled diabetes, liver disease)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Amgen</keyword>
	<keyword>chronic inflammatory disease</keyword>
	<keyword>wheezing</keyword>
</DOC>